par Bregni, Giacomo;Pretta, Andrea;Senti, Chiara 
;Acedo Reina, Elena ;Vandeputte, Caroline;Trevisi, Elena;Gkolfakis, Paraskevas;Kehagias, Pashalina ;Deleporte, Amélie;Van Laethem, Jean-Luc ;Vergauwe, Philippe;Van den Eynde, Marc;Deboever, Guido;Janssens, Jos;Demolin, Gauthier;Holbrechts, Stephane;Clausse, Marylene;De Grez, Thierry;Peeters, Marc;D'Hondt, Lionel;Geboes, Karen;Besse-Hammer, Tatiana;Rothé, Françoise;Flamen, Patrick;Hendlisz, Alain ;Sclafani, Francesco
Référence Acta oncologica, 61, 10, page (1223-1229)
Publication Publié, 2022-10
;Acedo Reina, Elena ;Vandeputte, Caroline;Trevisi, Elena;Gkolfakis, Paraskevas;Kehagias, Pashalina ;Deleporte, Amélie;Van Laethem, Jean-Luc ;Vergauwe, Philippe;Van den Eynde, Marc;Deboever, Guido;Janssens, Jos;Demolin, Gauthier;Holbrechts, Stephane;Clausse, Marylene;De Grez, Thierry;Peeters, Marc;D'Hondt, Lionel;Geboes, Karen;Besse-Hammer, Tatiana;Rothé, Françoise;Flamen, Patrick;Hendlisz, Alain ;Sclafani, Francesco Référence Acta oncologica, 61, 10, page (1223-1229)
Publication Publié, 2022-10
Article révisé par les pairs
| Résumé : | While circulating tumour (ct)DNA is an indicator of minimal residual disease and negative prognostic factor in stage II-III colon cancer, no study has ever analysed the value of this biomarker in colon cancer patients treated with neoadjuvant chemotherapy. We sought to fill this gap by using prospectively collected plasma samples from 80 stage III colon cancer patients, receiving one cycle of neoadjuvant FOLFOX followed by surgery +/- adjuvant FOLFOX in the PePiTA trial. |
